PE20070176A1 - Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n - Google Patents

Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n

Info

Publication number
PE20070176A1
PE20070176A1 PE2006000816A PE2006000816A PE20070176A1 PE 20070176 A1 PE20070176 A1 PE 20070176A1 PE 2006000816 A PE2006000816 A PE 2006000816A PE 2006000816 A PE2006000816 A PE 2006000816A PE 20070176 A1 PE20070176 A1 PE 20070176A1
Authority
PE
Peru
Prior art keywords
ona
piperidin
dihydro
replaced
benzimidazol
Prior art date
Application number
PE2006000816A
Other languages
English (en)
Inventor
Masaya Hashimoto
Yoshikazu Iwasawa
Hisashi Ohta
Takeshi Sagara
Atsushi Satoh
Hiroki Sakoh
Satoshi Ozaki
Hiroshi Kawamoto
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of PE20070176A1 publication Critical patent/PE20070176A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), EN DONDE R ES ALQUILO(C1-C6) SUSTITUIDO POR DIHIDROXI; Cy ES UN GRUPO CARBOCICLICO ALIFATICO BI O TRICICLICO (C6-C10), OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C4). SON PREFERIDOS: 1-(2,3-DIHIDROXIPROPIL)-3-[1-(ESPIRO[4.5]DEC-6-ILMETIL)PIPERIDIN-4-IL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, 1-(2,3-DIHIDROXIPROPIL)-3-[1-(ESPIRO[2.5]OCT-4-ILMETIL)PIPERIDIN-4-IL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, 1-[2-HIDROXI-1-(HIDROXIMETIL)ETIL]-3-[1-(ESPIRO[BICICLO-[2.2.1]HEPTANO-2,1'-CICLOPROPAN]-3-ILMETIL)PIPERIDIN-4-IL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE NOCICEPTINA ORL1 (RECEPTOR TIPO OPIOIDE-1) Y SON UTILES COMO AGENTES PARA ALIVIAR LA TOLERANCIA A ANALGESICOS NARCOTICOS REPRESENTADOS POR MORFINA, POTENCIADORES DE ANALGESIA, OBESIDAD, DIABETES INSIPIDA, PILIURIA, PARKINSON
PE2006000816A 2005-07-13 2006-07-10 Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n PE20070176A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005204264 2005-07-13

Publications (1)

Publication Number Publication Date
PE20070176A1 true PE20070176A1 (es) 2007-03-09

Family

ID=37637260

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000816A PE20070176A1 (es) 2005-07-13 2006-07-10 Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n

Country Status (23)

Country Link
EP (1) EP1914232B1 (es)
JP (1) JP4748162B2 (es)
KR (1) KR20080033262A (es)
CN (1) CN101223158B (es)
AR (1) AR054816A1 (es)
AU (1) AU2006267391B2 (es)
BR (1) BRPI0613109A2 (es)
CA (1) CA2614688A1 (es)
CR (1) CR9692A (es)
DE (1) DE602006018950D1 (es)
DO (1) DOP2006000165A (es)
EC (1) ECSP088096A (es)
ES (1) ES2355580T3 (es)
IL (1) IL188418A0 (es)
MA (1) MA29738B1 (es)
NI (1) NI200800003A (es)
NO (1) NO20080770L (es)
NZ (1) NZ565026A (es)
PE (1) PE20070176A1 (es)
RU (1) RU2414456C2 (es)
TW (1) TW200740436A (es)
WO (1) WO2007007890A1 (es)
ZA (1) ZA200711025B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033757A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100184673A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
RU2582339C2 (ru) * 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
PL3345907T3 (pl) * 2015-09-01 2020-09-07 Taiho Pharmaceutical Co., Ltd. Związki pirazolo[3,4-d]pirymidynowe lub ich sole
KR20240022630A (ko) * 2021-07-14 2024-02-20 이창 휴먼웰 파마슈티칼 코포레이션, 리미티드 피페리딘 유도체 및 그 약물 조성물, 제조 방법과 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200468A1 (en) * 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
EP0898568B1 (en) * 1996-04-19 2006-10-04 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
ATE276242T1 (de) * 1997-05-30 2004-10-15 Banyu Pharma Co Ltd 2-oxoimidazol-derivate
DK1049689T3 (da) * 1998-01-19 2002-07-22 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
JP2003524634A (ja) * 1999-12-06 2003-08-19 ユーロ−セルティーク，エス．エイ． ノシセプチン受容体親和性を有するベンズイミダゾール化合物

Also Published As

Publication number Publication date
ZA200711025B (en) 2008-12-31
AR054816A1 (es) 2007-07-18
CN101223158A (zh) 2008-07-16
AU2006267391A1 (en) 2007-01-18
TW200740436A (en) 2007-11-01
EP1914232B1 (en) 2010-12-15
ES2355580T3 (es) 2011-03-29
AU2006267391B2 (en) 2011-12-08
NI200800003A (es) 2008-07-21
NO20080770L (no) 2008-04-11
CR9692A (es) 2008-02-21
KR20080033262A (ko) 2008-04-16
DOP2006000165A (es) 2007-02-28
CA2614688A1 (en) 2007-01-18
IL188418A0 (en) 2008-11-03
RU2414456C2 (ru) 2011-03-20
EP1914232A1 (en) 2008-04-23
WO2007007890A1 (ja) 2007-01-18
ECSP088096A (es) 2008-02-20
EP1914232A4 (en) 2009-10-28
RU2008105396A (ru) 2009-08-20
NZ565026A (en) 2010-09-30
DE602006018950D1 (de) 2011-01-27
JPWO2007007890A1 (ja) 2009-01-29
BRPI0613109A2 (pt) 2012-12-04
JP4748162B2 (ja) 2011-08-17
MA29738B1 (fr) 2008-09-01
CN101223158B (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
PE20071311A1 (es) Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu
ECSP067082A (es) Antagonistas de receptor de glucagon, preparacion y usos terapeuticos
EA201300869A1 (ru) Морфинановые соединения
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
PE20120413A1 (es) ENANTIOMERO (S) DE 1'-{[5-(TRIFLUOROMETIL)FURAN-2-IL]METIL}ESPIRO[FURO[2,3-f][1,3]BENZODIOXOL-7,3'-INDOL]-2'(1'H)-ONA
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
PE20070176A1 (es) Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
PE20081837A1 (es) Derivados de quinuclinidol como antagonistas de los receptores muscarinicos
AR083831A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
CO6140054A2 (es) Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR050914A1 (es) Agonista receptor de vasopresina peptidico
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
AR100530A1 (es) Compuestos antihelmínticos
GB0701365D0 (en) Novel pharmaceutical compositions
PE20121556A1 (es) 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
CL2011000533A1 (es) Compuestos derivados de isoquinolina sustituida; antagonista nk3; composicion farmaceutica que lo comprende; y uso en el tratamiento de enfermedades tales como psicosis, esquizofrenia, alzheimer, parkinson, entre otras.
PE20050231A1 (es) Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
AR075160A1 (es) Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed